ABSTRACT Stigmasterol glucoside (SG), a phytosterol glycoside derived from plants, is widely distributed in numerous natural sources—particularly medicinal and edible plants—and is recognized to possess potential anti‐inflammatory properties, although its mechanisms of action remain incompletely understood. Experimental results demonstrated that SG significantly attenuated lipopolysaccharide (LPS)‐induced inflammatory responses in RAW264.7 macrophages. In a murine model of systemic inflammatory response syndrome (SIRS) established by LPS challenge, SG effectively mitigated systemic inflammation and ameliorated LPS‐induced hepatic dysfunction. Integrated network pharmacological analysis and transcriptomic sequencing revealed that SG primarily exerts its anti‐inflammatory activity through modulation of the mitogen‐activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3) signaling pathways, thereby conferring protection against liver injury and systemic inflammation. These findings highlight SG as a promising therapeutic candidate for inflammation‐related disorders.
Liu et al. (Wed,) studied this question.